Show simple item record

dc.contributor.advisorChairperson, Graduate Committee: Margaret Hammerslaen
dc.contributor.authorGalahan, Alicia Marieen
dc.date.accessioned2022-02-09T18:37:44Z
dc.date.available2022-02-09T18:37:44Z
dc.date.issued2021en
dc.identifier.urihttps://scholarworks.montana.edu/xmlui/handle/1/16257en
dc.description.abstractAtypical antipsychotics are commonly used to treat a variety of mental health disorders in children and adolescents. Prescribing atypical antipsychotics is not without risk as the development of metabolic side effects can lead to reduced life expectancy from chronic metabolic diseases. The metabolic side effects from atypical antipsychotics are considered treatable medical conditions requiring appropriate screening and intervention. Despite recommendations, psychiatric providers do not consistently screen and treat metabolic abnormalities, creating a gap in care for these individuals. This quality improvement project took place on an adolescent inpatient residential unit. This project focused on incorporating recommendations from clinical practice guidelines by focusing on improving rates of metabolic screening and utilization of treatment interventions when metabolic abnormalities are identified to reduce the burden of metabolic side effects for patients. The Plan-Do-Study-Act framework was used to guide this quality improvement project over six weeks with four separate cycles varying in duration from one to two weeks each. A metabolic screening bundle for psychiatric provider notes was created within the electronic health record to improve ease of interpreting metabolic screening values and identifying need for further intervention. At the end of the quality improvement project, rates of metabolic screening remained unchanged. The rate of patients receiving treatment interventions increased and multiple patients received more than one treatment intervention. Treatment modalities studied included metformin, individual physical activity, and nutritionist consult. This quality improvement project sought to decrease patients experiencing metabolic abnormalities after treatment with atypical antipsychotic medication, but effectiveness was unable to be measured due to the short time frame. Metabolic screening is a necessary part of atypical antipsychotic treatment that needs to be completed upon initiation of medication and at future appointments. Once metabolic screening is completed, further education on potential treatment interventions for metabolic abnormalities needs to be discussed with the patient and other professionals involved in their care to improve patient outcomes.en
dc.language.isoenen
dc.publisherMontana State University - Bozeman, College of Nursingen
dc.subject.lcshAntipsychotic drugsen
dc.subject.lcshDrugs--Side effectsen
dc.subject.lcshMetabolism--Disordersen
dc.subject.lcshMedical screeningen
dc.subject.lcshMental healthen
dc.subject.lcshTherapeuticsen
dc.titleImproving treatment of metabolic side effects from atypical antipsychoticsen
dc.typeDissertationen
dc.rights.holderCopyright 2021 by Alicia Marie Galahanen
thesis.degree.committeemembersMembers, Graduate Committee: Sandra Benavides-Vaello; Casey Coleen
thesis.degree.departmentNursing.en
thesis.degree.genreDissertationen
thesis.degree.nameDoctor of Nursing Practice (DNP)en
thesis.format.extentfirstpage1en
thesis.format.extentlastpage48en
mus.data.thumbpage29en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record


MSU uses DSpace software, copyright © 2002-2017  Duraspace. For library collections that are not accessible, we are committed to providing reasonable accommodations and timely access to users with disabilities. For assistance, please submit an accessibility request for library material.